Nine studies (n=381: 230 with acute AD and 151 with chronic AD) were included in the review. Reported cumulative doses ranged from 24.8 to 1,950 J/cm2, and treatment durations varied between 10 days and 12 weeks, or until clearance. The sample sizes ranged from 9 to 120 patients. Three studies reported follow-up at 1, 3 or 6 months.
Treatment of acute AD with UVA1 (3 trials).
Trends suggested that phototherapy with UVA1 is more effective than UVAB and topical corticosteroids. UVA1 response times were faster in comparison with UVAB, with peak response after 10 treatments. One study reported UVA1c to be slightly more effective in reducing the severity of acute AD compared with UVA1 up to 1 month post-treatment.
One study reported no significant differences between high-, medium- and low-doses of UVA1, while one study reported a greater reduction in the SCORAD index after 3 weeks of treatment using medium compared with low doses.
Treatment of chronic AD with UV phototherapy (4 trials).
Significant differences were reported between UVAB and UVB scores, with greater improvements observed in pruritis or healing scores, overall evaluation and total scores using UVAB. Two studies reported significant improvements in disease activity using narrow-band UVB compared with UVA, medium-dose UVA1 and visible light therapy.
Side-effects and patient opinions were reported in the review.